Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07527299 · ClinicalTrials.gov registry record · NA
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation
A NA study, sponsored by Biosense Webster.
- Recruiting
- Registry status
- NA
- Development phase
- 920
- Enrollment target
NCT07527299 is a NA study that is actively recruiting participants, run by Biosense Webster. The registered enrollment target is 920 participants.
The verdict
NCT07527299, a NA study, is actively recruiting participants, sponsored by Biosense Webster.
- RECRUITING
- Registry status
- NA
- Development phase
- 920 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; PVI and SVCI), with or without another technique called posterior wall isolation (PWI). Also, to assess how safe it is for participants who are having a catheter ablation procedure and at the same time receiving another procedure called left atrial appendage occlusion (LAAO; to reduce stroke risk). Additionally, to assess how well VARIPULSE catheter system works over a long period of time for treatment of PsAF in participants undergoing catheter ablation.
Interventions
- DEVICE VARIPULSE Catheter System
- DEVICE LAAO Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 920 participants |
| Start Date | 2026-08-05 |
| Est. Completion | 2031-08-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07527299
The ClinicalTrials.gov registry entry for NCT07527299 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 920 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosense Webster, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VARIPULSE Catheter System is the first listed.
NCT07527299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07527299 about?
NCT07527299 is a clinical study titled "A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation". The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and s...
What is the current status of trial NCT07527299?
This trial is currently recruiting. It is a NA study. The enrollment target is 920 participants. The study started on 2026-08-05. Estimated completion is 2031-08-04.
What interventions are being tested in trial NCT07527299?
The interventions under investigation include: VARIPULSE Catheter System (DEVICE), LAAO Device (DEVICE).
Who is sponsoring clinical trial NCT07527299?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.